BioNTech’s $1B Buyback Mandate Secured, but All Eyes Turn to Lung Cancer Data

With 92% capital backing, BioNTech approves $1B buyback and board expansion. Stock down 8% monthly, hinges on ASCO lung cancer data for turnaround.

BioNTech’s shareholders delivered a near-unanimous endorsement of management’s strategy on Friday, approving a $1 billion share repurchase program and expanding the supervisory board. The show of confidence, with 92% of capital represented at the annual general meeting, stands in stark contrast to a stock that has shed 8% over the past month and continues to trade below key technical levels. The disconnect underscores just how much the narrative now hinges on clinical progress rather than financial engineering.

Behind the vote lies a company sitting on a cash pile of roughly €16.8 billion, much of it accumulated during the pandemic. That war chest allows BioNTech to fund its oncology pivot without external financing, even as the Covid-driven revenue stream dwindles. First-quarter sales slid to €118.1 million from €182.8 million a year earlier, a decline that highlights the urgency of the pipeline transition. For the full year 2026, management expects revenue of $2.3–$2.6 billion (€2.0–€2.3 billion), while R&D spending is planned at up to €2.5 billion in 2026 alone. Cost-cutting measures are also underway, with a goal of meaningfully lowering annual expenses by 2029.

The stock’s technical picture remains fragile. After closing at €76.95 on Friday, down 2.22% on the day, the shares are now more than 11% below their 200-day moving average. A break below the support level at €72.50 — a zone that has held in the past — could trigger further selling pressure.

The next real catalyst arrives before the month is out. At the ASCO congress starting late May, BioNTech will present Phase 2 data from the ROSETTA-Lung-02 study, evaluating pumitamig in combination with chemotherapy against the standard of care pembrolizumab plus chemotherapy in lung cancer. The trial is part of a broader oncology push that also includes the bispecific antibody BNT327 and the mRNA platform FixVac. Positive results could provide the spark the stock desperately needs.

Meanwhile, a leadership change looms. Founders Ugur Sahin and Özlem Türeci are set to move into new roles by year-end, a transition that signals BioNTech’s preparation for the planned market launch of its first cancer immunotherapy. The management shake-up, along with the supervisory board’s expansion to eight members, gives the company the governance structure it believes is needed for the long haul.

Analyst opinions on BioNTech’s prospects diverge sharply. Canaccord maintains a “Buy” rating with a price target of $158, betting on pipeline success. Leerink is far more cautious, setting a target of just $94. That wide gap illustrates how heavily the valuation now depends on whether the clinical data can turn the oncology story into a commercial reality. For now, shareholders have backed the plan — but the stock will be the ultimate judge.